Skip to main content

Table 5 Association of loss of vascular access patencya with attribution of ESRD to SLE vs. other causes, among 2010 U.S. incident hemodialysis patients who started dialysis with a permanent vascular access: sensitivity analyses

From: Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Model No. (%) with access revision within 1 year Hazard ratio (95 % CI) for loss of patency, SLE-attributed vs. other ESRD
Unadjusted Adjusted for demographics Adjusted for demographics + clinical
Primary analysis     
 SLE-attributed ESRD 21 (43.8 %) 0.70 (0.45-1.09) 0.81 (0.52-1.26) 0.88 (0.57-1.37)
 Other ESRD 7,169 (55.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 P 0.12 0.11 0.35 0.58
Excluding patients <18 years oldb     
 SLE-attributed ESRD 21 (43.8 %) 0.70 (0.45-1.08) 0.81 (0.52-1.26) 0.88 (0.57-1.37)
 Other ESRD 7,165 (55.1 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 P 0.12 0.11 0.35 0.57
Only among patients with Medicare at ESRD startc     
 SLE-attributed ESRD ---d 0.91 (0.55-1.52) 0.86 (0.52-1.42) 0.92 (0.55-1.53)
 Other ESRD 1125 (13.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 P 0.76 0.73 0.55 0.75
SLE and other GN compared to other ESRDe     
 SLE-attributed ESRD ---d 0.69 (0.44-1.07) 0.80 (0.52-1.24) 0.87 (0.56-1.35)
 Other GN-attributed ESRD 60 (6.9 %) 0.79 (0.71-0.88) 0.87 (0.78-0.96) 0.91 (0.82-1.02)
 Other ESRD 1433 (11.8 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 P <0.001 0.10/<0.001 0.32/0.008 0.54/0.09
Matched analysisf     
 SLE-attributed ESRD 21 (43.8 %) 0.71 (0.42-1.19) 0.70 (0.42-1.15) 0.81 (0.47-1.40)
 Other ESRD 89 (58.2 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 P 0.08 0.19 0.16 0.46
Events prior to 90 days included on day 91     
 SLE-attributed ESRD 21 (43.8 %) 0.73 (0.47-1.13) 0.81 (0.52-1.27) 0.88 (0.57-1.37)
 Other ESRD 7,169 (55.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 P 0.12 0.16 0.36 0.57
Events prior to 90 days excludedg     
 SLE-attributed ESRD 13 (32.5 %) 0.85 (0.49-1.46) 0.76 (0.44-1.31) 0.84 (0.48-1.45)
 Other ESRD 3,377 (36.6 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
 P 0.59 0.56 0.32 0.52
  1. AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, GN glomerulonephritis, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
  2. aDefined as a revision or placement of a new AVF, AVG, or catheter (see Table 1)
  3. bExcluding n = 14 patients (4 SLE, 10 other) who were <18 years old
  4. cExcluding n = 4,375 patients (23 SLE, 4,352 other) without Medicare at ESRD start
  5. dNot reportable due to cell size < 10
  6. eOther GN included 864 patients with CMS-2728 ICD-9 codes for attributed cause of glomerulonephritis (582.9, 582.1, 583.1, 583.21, 583.22, 583.81, 583.82, 583.4, 580.0, and 582.0) or secondary glomerulonephritis/vasculitis (excluding SLE-ESRD; 287.0, 710.1, 283.11, 446.0, 446.4, 583.92, 446.20, 446.21, and 583.91)
  7. fAmong n = 201 patients, including 48 SLE patients and 153 matched non-SLE patients, using 2:1 matching on age group (<30, 30–49, and >50 years), sex (female and male), and race (black and not black). Models stratified on matching variable to account for matching
  8. gExcluding n = 3,801 patients (35 SLE, 8,456 other) with follow-up time <90 days
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us